J
Jeremy Millar
Researcher at Monash University
Publications - 201
Citations - 6907
Jeremy Millar is an academic researcher from Monash University. The author has contributed to research in topics: Prostate cancer & Population. The author has an hindex of 31, co-authored 169 publications receiving 6074 citations. Previous affiliations of Jeremy Millar include Alfred Hospital & Wellington Hospital.
Papers
More filters
Journal ArticleDOI
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Bryan Burmeister,B. Mark Smithers,Val Gebski,Lara Fitzgerald,R. John Simes,Peter G. Devitt,Stephen P. Ackland,David C. Gotley,David Joseph,Jeremy Millar,John B. North,Euan Walpole,James W. Denham +12 more
TL;DR: Preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone, and further assessment is warranted of the role of cheMoradiotherapy in patients with squamous-cell tumours.
Journal ArticleDOI
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P. Dearnaley,Matthew R. Sydes,John Graham,Edwin Aird,David Bottomley,Richard A Cowan,Robert Huddart,Chakiath C Jose,John H L Matthews,Jeremy Millar,A. Rollo Moore,Rachel C Morgan,J. Martin Russell,Christopher D Scrase,Richard Stephens,Isabel Syndikus,Mahesh K. B. Parmar +16 more
TL;DR: The first analyses of effectiveness from the MRC RT01 randomised controlled trial are presented, finding Escalated-dose CFRT with neoadjuvant androgen suppression seems clinically worthwhile in terms of bPFS, progression-free survival, and decreased use of salvage androgens suppression.
Journal ArticleDOI
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Peter D. Grimm,Ignace Billiet,David Bostwick,Adam P. Dicker,Steven J. Frank,Jos Immerzeel,Mira Keyes,Patrick A. Kupelian,W. Robert Lee,Stefann Machtens,Jyoti Mayadev,Brian J. Moran,Gregory S. Merrick,Jeremy Millar,Mack Roach,Richard G. Stock,Katsuto Shinohara,Mark Scholz,Ed Weber,Anthony L. Zietman,Michael J. Zelefsky,Jason Wong,Stacy Wentworth,Robyn Vera,Stephen E.M. Langley +24 more
TL;DR: The largest ever study of its kind has been conducted on the role of language and culture in the development of Alzheimer's disease and its effects on memory and language impairment.
Journal ArticleDOI
Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade
Jayne S. Sutherland,Gabrielle L. Goldberg,Maree V. Hammett,Adam P Uldrich,Stuart P. Berzins,Tracy Heng,Bruce R. Blazar,Jeremy Millar,M A Malin,Ann P. Chidgey,Richard L. Boyd +10 more
TL;DR: It is demonstrated that androgen ablation results in the complete regeneration of the aged male mouse thymus, restoration of peripheral T cell phenotype and function and enhancedThymus regeneration following bone marrow transplantation.
Journal Article
AN UPDATE OF THE PHASE III TRIAL COMPARING WHOLE PELVIC TO PROSTATE ONLY RADIOTHERAPY AND NEOADJUVANT TO ADJUVANT TOTAL ANDROGEN SUPPRESSION : UPDATED ANALYSIS OF RTOG 94-13, WITH EMPHASIS ON UNEXPECTED HORMONE/ RADIATION INTERACTIONS: IN REGARD TO LAWTON ET AL. Author's reply
TL;DR: Unexpected interactions appear to exist between the timing of hormonal therapy and radiation field size for this patient population and additional studies are warranted to determine whether the failure to demonstrate an advantage for NHT + WPRT compared with PORT + AHT is chance or, more likely, reflects a previously unrecognized biologic phenomenon.